Galderma Research & Development

Galderma Research & Development Snc

Rhodia Chimie

Thibaud Biadatti

Etienne Thoreau

Sandrine Talano

Laurence Dumais

Sebastien Daver

Catherine Soulet

Jean-Marie Arlabosse

Jean-Michel Bernardon

Philippe Diaz

Pascal Collette

Catherine Raffin

Dominique Charmot

Samir Z Zard

Andre Jomard

Johannes Voegel

Olivier Roye

Pascale Corpart

Anne-Pascale Luzy

Daniel Michelet

Sébastien Daver

Novel ligand compounds having the structural formula (I): in which: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine, or, alternatively into cosmetic compositions.

Ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof

Novel ligand compounds having the general formula (I): and pharmaceutical/cosmetic compositions comprised thereof are useful in human and veterinary medicine or, alternatively, in cosmetics.

Ligands that modulate RAR receptors

Biphenyl compounds having the formula (I): are useful for preventing/treating pathologies linked to a deficiency of the activation of the RAR gamma receptor, e.g., for treating a pathology linked to a cell differentiation and/or proliferation disorder, for treating acne, for treating psoriasis.

Biphenyl compound selective agonists of gamma RAR receptors

Novel ligand compounds having the structural formula (I): in which: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine, or, alternatively, into cosmetic compositions.

Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof

Novel ligand compounds having the structural formula (I): in which: Ar is a radical selected from among the radicals of formulae (a)-(c) below: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine, or, alternatively into cosmetic compositions.

Novel ligand antagonists of the RAR receptors have the following structural formula (I): in which A is a CH, CHOH, C&#x2550;O or C&#x2550;N&#x2014;OH radical or a sulfur or selenium atom; B is a radical selected from among those of formulae (a) to (f): and Ar is a radical selected from among those of formulae (g) to (i): 

Ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof

Novel biaryl compounds having the structural formula (I): are useful in a variety of pharmaceutical applications, whether human or veterinary, and also in cosmetics.

Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof

Novel ligand compounds that activate RAR receptors have the following structural formula (I): and are suited for formulation into pharmaceutical compositions useful in human or veterinary medicine, or, alternatively, into cosmetic compositions.

Pharmaceutical/cosmetic compositions comprising novel ligands that activate RAR receptors

Novel bicyclic compounds having the structural formula (I): are useful in a variety of pharmaceutical applications, whether human or veterinary, and also in cosmetics.

Growing community of inventors

Opio, France

Thibaud Biadatti